ADRA1A

ADRA1A (α1A-adrenergic receptor) is a Gαq-coupled G protein-coupled receptor activated by noradrenaline that transduces sympathetic signals into diverse tissue-specific cellular responses, including thermogenesis, secretory regulation, calcium-dependent gliotransmission, and metabolic homeostasis. In adipocytes, ADRA1A physically couples to Gαq to drive energy expenditure through the futile creatine cycle requiring creatine kinase B (CKB) and tissue-non-specific alkaline phosphatase (TNAP) (PMID:36344764); in lacrimal gland acinar and myoepithelial cells, it suppresses tear secretion via mitochondrial Ucp2, and its pharmacological, surgical, or genetic blockade alleviates dry eye (PMID:40473608). ADRA1A functions upstream of AMPK signaling in hepatic and cardiac contexts and exerts a cardioprotective role, as Adra1a deficiency exacerbates angiotensin II-driven cardiac hypertrophy in pregnancy-associated hypertensive mice (PMID:36736425, PMID:34706275). ADRA1A expression is post-transcriptionally regulated by multiple miRNAs including miR-19b, miR-16, miR-661, and miR-3682 (PMID:28531963, PMID:37820700, PMID:34706275), and the gene produces multiple alternatively spliced isoforms generated through transposable element integration, differential promoter usage, and splice-site variation (PMID:20410666).

1. 2010 Medium

   Establishing that ADRA1A generates transcript diversity through TE integration and splice-site evolution answered how a single GPCR gene produces functionally distinct isoforms across tissues.

   Evidence RT-PCR and sequencing validation of six alternative transcripts arising from AluSc/L1MC5/MIR3 integration, differential promoters, and alternative 3' splice sites in human tissues

   PMID:20410666

   Open questions at the time

   • Functional consequences of individual isoforms not characterized
   • Tissue-specific isoform expression profiles not systematically quantified
   • Protein-level validation of alternative isoforms not performed
2. 2017 Medium

   Demonstration that miR-19b and miR-16 cooperatively suppress ADRA1A expression to promote cardiac apoptosis and fibrosis revealed a post-transcriptional regulatory axis for receptor abundance in hypertensive heart disease.

   Evidence miRNA inhibitor rescue in DOCA-induced hypertensive mice showing increased ADRA1A protein and decreased caspase 3/7 activity and fibrosis

   PMID:28531963

   Open questions at the time

   • Direct 3'UTR targeting by miR-19b/16 not validated by luciferase reporter in this study
   • Mechanism linking restored ADRA1A to anti-apoptotic signaling not delineated
   • Single disease model
3. 2021 Medium

   Identification of miR-3682 as a direct negative regulator of ADRA1A and placement of ADRA1A upstream of AMPK signaling in hepatocellular carcinoma cells established ADRA1A as a signaling node in the AMPK pathway beyond its classical Gαq coupling.

   Evidence Dual-luciferase reporter assay confirming miR-3682 targeting of ADRA1A 3'UTR, siRNA knockdown epistasis, and Western blot of AMPK pathway in HCC cells

   PMID:34706275

   Open questions at the time

   • ADRA1A-AMPK coupling mechanism (direct vs. indirect) not resolved
   • In vivo validation in liver tissue not performed
   • Single cancer cell line context
4. 2022 High

   Physical coupling of ADRA1A to Gαq in adipocytes and functional requirement of the futile creatine cycle (CKB/TNAP) for receptor-driven thermogenesis provided the first tissue-specific effector pathway linking α1A-adrenergic signaling to whole-body energy expenditure.

   Evidence Co-immunoprecipitation of ADRA1A-Gαq, adipocyte-selective CKB knockout abolishing energy expenditure, and pharmacological receptor subtype dissection in mice

   PMID:36344764

   Open questions at the time

   • Whether Gαq-creatine cycle coupling occurs in non-adipocyte tissues unknown
   • Structural basis of ADRA1A-Gαq selectivity not resolved
   • Human translational relevance not demonstrated
5. 2023 Medium

   Loss of Adra1a in pregnancy-associated hypertensive mice exacerbated Ang II-driven cardiac hypertrophy, establishing a cardioprotective function for Adra1a and its regulation by the renin-angiotensin system.

   Evidence Adra1a knockout in PAH mouse model with cardiac hypertrophy phenotyping and gene expression analysis

   PMID:36736425

   Open questions at the time

   • Downstream signaling pathway mediating cardioprotection not identified
   • Whether RAS regulation of Adra1a is transcriptional or post-transcriptional not determined
   • Relevance to human preeclampsia not tested
6. 2023 Medium

   Validation that miR-661 directly targets the ADRA1A 3'UTR and that ADRA1A overexpression suppresses lung cancer cell proliferation added another miRNA regulatory axis and suggested a tumor-suppressive role for ADRA1A in a non-cardiovascular context.

   Evidence Dual-luciferase reporter and RIP assay confirming miR-661 binding, epistasis by miR-661 re-introduction reversing ADRA1A-mediated growth suppression, in vivo tumor model

   PMID:37820700

   Open questions at the time

   • Mechanism by which ADRA1A suppresses proliferation in lung cancer cells unknown
   • Whether this is ligand-dependent or constitutive activity not addressed
   • Single cell line and xenograft model
7. 2025 High

   Demonstration that ADRA1A in lacrimal gland acinar and myoepithelial cells regulates mitochondrial Ucp2 to suppress tear secretion, and that its blockade rescues dry eye, defined an unexpected secretory-regulatory function for the receptor.

   Evidence Pharmacological blockade (silodosin, tamsulosin), surgical sympathectomy, and genetic knockout in dry eye mouse models with immunofluorescence localization

   PMID:40473608

   Open questions at the time

   • How ADRA1A-Gαq signaling regulates Ucp2 expression or activity not elucidated
   • Human clinical validation pending
   • Whether other α1-adrenergic subtypes contribute in the lacrimal gland not fully excluded

• The precise signaling intermediates linking ADRA1A to AMPK activation, the structural basis of ADRA1A's tissue-specific effector coupling (creatine cycle in adipocytes, Ucp2 in lacrimal gland), and the functional significance of its multiple splice isoforms remain unresolved.
• No structural model of ADRA1A-Gαq complex
• ADRA1A-AMPK signaling intermediates unidentified
• Functional roles of individual splice isoforms not tested
• In vivo relevance of miRNA regulation in non-disease physiology not established